Zevra Therapeutics, Inc. (ZVRA) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-09

Business type: Asset play

How it makes money

Patients and insurers pay for treatments that address rare, progressive neurodegenerative and metabolic disorders.

Revenue is generated through the sale of drugs like MIPLYFFA and OLPRUVA to those with rare diseases.

Success depends on third-party payors, including government programs and private insurers, providing coverage and adequate reimbursement for these costly therapies.

What protects it: the moat

MIPLYFFA has been granted orphan medicinal product designation by the European Commission.

This designation is a regulatory status in Europe that provides certain advantages for drugs treating rare diseases.

It helps protect the product's market position as it pursues regulatory approval in the E.U.

What growth costs

It must invest in clinical trials and commercial infrastructure to develop and sell its drugs.

To grow, Zevra must fund the development of new drug candidates through preclinical and clinical studies.

It also needs to build and maintain a specialized sales and medical affairs team to support product commercialization.

What could damage it

If third-party payors refuse coverage or low reimbursement, the company's ability to generate revenue is impaired.

Pharmaceutical sales depend on insurance companies and government programs paying for the drugs.

If these payors decide not to cover a product or place it on a high-cost tier, patients and doctors are unlikely to use it.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Other companies in Biotechnology